Preclinical studies using transgenic mice expressing human CD19 have shown that pre-B cells and their malignant counterparts, as well as pre-existing antibody-producing and autoantibody-producing ...

Approval was supported by the single-arm, multicenter FELIX trial, which enrolled patients with relapsed or refractory ...

CD19, a B-cell surface protein, is expressed across B-cell development and it is expressed on almost all B-cell malignancies, such as ALL, chronic lymphocytic leukemia (CLL) and several non ...

The U.S. FDA has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma ...

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer Twenty-eight patients underwent apheresis and received CAR T cells. Sixteen and 12 patients ...

analysis of anti-CD19 CAR-T cells in clinical trials. With positive feedback related to its high-affinity CD19 proteins available in the market, ACROBiosystems has now created an anti-idiotypic ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...